<DOC>
	<DOCNO>NCT02073656</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) administer 12 week hepatitis C virus ( HCV ) treatment-naive treatment-experienced ( include treatment intolerant ) participants chronic genotype 1 4 HCV infection co-infected HIV-1 . Participants experience confirm post-treatment virologic failure ( relapse ) Posttreatment Week 24 may eligible enrolled Retreatment Substudy receive LDV/SOF plus ribavirin ( RBV ) 24 week .</brief_summary>
	<brief_title>Efficacy Safety Ledipasvir/Sofosbuvir Fixed-Dose Combination 12 Weeks Subjects With Chronic Genotype 1 4 HCV HIV-1 Co-infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>HCV RNA â‰¥ 10,000 IU/mL screen HCV genotype 1 4 HIV1 infection Cirrhosis determination , fibroscan liver biopsy may require Screening laboratory value within define threshold Use protocol specify method ( ) contraception female childbearing potential sexually active male Clinicallysignificant illness ( HCV HIV ) major medical disorder may interfere subject treatment , assessment , compliance protocol Current prior history clinical hepatic decompensation , hepatocellular carcinoma ( HCC ) , malignancy ( exception certain resolve skin cancer ) Hepatitis B virus ( HBV ) infection Pregnant nursing female Chronic use systemically administer immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>genotype 1</keyword>
	<keyword>genotype 4</keyword>
	<keyword>HIV</keyword>
</DOC>